We analyzed breast cancer samples from public databases and found no notable differences in KLF5 expression between the residual disease (RD) and pathological complete response (pCR) groups after neoadjuvant chemotherapy in all breast cancer samples (Fig. 1A). This evidence concerns the gene KLF5 and breast cancer.